Want to see GB:FAB full AI Analyst Report?
Total Valuation
Fusion Antibodies Plc has a market cap or net worth of £15.02M. The enterprise value is 13.92 p.
Market Cap£15.02M
Enterprise Value13.92 p
Share Statistics
Fusion Antibodies Plc has 125,156,876 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding125,156,876
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Fusion Antibodies Plc’s return on equity (ROE) is -0.71 and return on invested capital (ROIC) is -99.85%.
Return on Equity (ROE)-0.71
Return on Assets (ROA)-0.42
Return on Invested Capital (ROIC)-99.85%
Return on Capital Employed (ROCE)-1.05
Revenue Per Employee78.15K
Profits Per Employee-42.56K
Employee Count27
Asset Turnover0.77
Inventory Turnover2.78
Valuation Ratios
The current PE Ratio of Fusion Antibodies Plc is ―. Fusion Antibodies Plc’s PEG ratio is 0.28.
PE Ratio―
PS Ratio6.83
PB Ratio8.89
Price to Fair Value8.89
Price to FCF-12.33
Price to Operating Cash Flow-12.23
PEG Ratio0.28
Income Statement
In the last 12 months, Fusion Antibodies Plc had revenue of 2.11M and earned -1.15M in profits. Earnings per share was -0.01.
Revenue2.11M
Gross Profit1.10M
Operating Income-1.98M
Pretax Income-1.15M
Net Income-1.15M
EBITDA-1.85M
Earnings Per Share (EPS)-0.01
Cash Flow
In the last 12 months, operating cash flow was -1.11M and capital expenditures -60.00K, giving a free cash flow of -1.17M billion.
Operating Cash Flow-1.11M
Free Cash Flow-1.17M
Free Cash Flow per Share>-0.01
Dividends & Yields
Fusion Antibodies Plc pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.43
52-Week Price Change-31.34%
50-Day Moving Average10.95
200-Day Moving Average12.73
Relative Strength Index (RSI)51.33
Average Volume (3m)469.16K
Important Dates
Fusion Antibodies Plc upcoming earnings date is Dec 7, 2026, TBA (Confirmed).
Last Earnings DateSep 14, 2026
Next Earnings DateDec 7, 2026
Ex-Dividend Date―
Financial Position
Fusion Antibodies Plc as a current ratio of 2.82, with Debt / Equity ratio of 20.41%
Current Ratio2.82
Quick Ratio2.39
Debt to Market Cap<0.01
Net Debt to EBITDA0.38
Interest Coverage Ratio-99.05
Taxes
In the past 12 months, Fusion Antibodies Plc has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Fusion Antibodies Plc EV to EBITDA ratio is -7.39, with an EV/FCF ratio of -11.72.
EV to Sales6.49
EV to EBITDA-7.39
EV to Free Cash Flow-11.72
EV to Operating Cash Flow-12.35
Balance Sheet
Fusion Antibodies Plc has £1.04M in cash and marketable securities with £331.00K in debt, giving a net cash position of £712.00K billion.
Cash & Marketable Securities£1.04M
Total Debt£331.00K
Net Cash£712.00K
Net Cash Per Share<£0.01
Tangible Book Value Per Share£0.01
Margins
Gross margin is 52.32%, with operating margin of -93.89%, and net profit margin of -54.45%.
Gross Margin52.32%
Operating Margin-93.89%
Pretax Margin-54.45%
Net Profit Margin-54.45%
EBITDA Margin-87.87%
EBIT Margin-93.89%
Analyst Forecast
The average price target for Fusion Antibodies Plc is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast7.38%
EPS Growth Forecast44.13%